Literature DB >> 27461601

Oxaliplatin-induced acute thrombocytopenia.

Gokmen Umut Erdem1, Mutlu Dogan1, Nebi Serkan Demirci1, Nurullah Zengin1.   

Abstract

Oxaliplatin (1, 2-diamminocyclohexaneoxalato-platinum) is a novel platin analog, which is widely used in gastrointestinal malignancies. Platinum analogs damage cellular deoxyribonucleic acid (DNA) by leading covalent bifunctional DNA adducts with cellular DNA. Major side effects of oxaliplatin are neurotoxicity (peripheral neuropathy), myelosuppression with moderate thrombocytopenia and gastrointestinal toxicity (diarrhea). Thrombocytopenia might be related to myelosuppression and/or drug-induced immune thrombocytopenia (DIIT). In here, oxaliplatin-induced thrombocytopenia is discussed with review of the literature.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27461601     DOI: 10.4103/0973-1482.154056

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  4 in total

Review 1.  Drug-associated thrombocytopenia.

Authors:  Tamam Bakchoul; Irene Marini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.

Authors:  Zaoqin Yu; Rui Huang; Li Zhao; Ximin Wang; Xiaofang Shangguan; Wei Li; Min Li; Xianguo Yin; Chengliang Zhang; Dong Liu
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

3.  Oxaliplatin-induced thrombotic microangiopathy: a case report.

Authors:  Rhea Saad; Audra Hannun; Sally Temraz; Antoine Finianos; Rony M Zeenny
Journal:  J Med Case Rep       Date:  2022-03-19

4.  Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome.

Authors:  Chen Zhu; Xinwei Cheng; Ping Gao; Qianyan Gao; Ximin Wang; Dong Liu; Xiuhua Ren; Chengliang Zhang
Journal:  Mol Med Rep       Date:  2022-09-30       Impact factor: 3.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.